Astria Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Astria Therapeutics

11/05/2023 22:31

* Astria Therapeutics Inc  ATXS.OQ  reported a quarterly
adjusted
loss of 40 cents​​ per share for the quarter ended in March. The
mean expectation of six analysts for the quarter was for a loss
of 55 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Astria Therapeutics Inc's reported EPS for the quarter was
a
loss of 40 cents​.
    * The mean earnings estimate of analysts had risen by
about 5.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Astria Therapeutics Inc shares had fallen by 5.7% this
quarter and lost 15.7% so far this year.
    * The company reported a quarterly loss of $11.19 million.
    * Wall Street's median 12-month price target for Astria
Therapeutics Inc is $23.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 09:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.55          -0.40          Beat
 Dec. 31 2022      -0.71          -0.72          Missed
 Sep. 30 2022      -0.92          -0.87          Beat
 Jun. 30 2022      -1.01          -0.86          Beat